UPCC 05818: A phase I/II study to evaluate the safety pharmacodynamics and efficacy of atezolizumab in combination with entinostat and bevacizumab in patients with advanced renal cell carcinoma
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
- Study Identifier: 829522
Recruitment StatusEnrolling By Invitation
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com